ALBA Network
Online Exhibition

The ALBA Network was created to promote equity and diversity in the brain sciences. The goals of ALBA are to recognize implicit bias and discrimination, and to provide better visibility and professional development opportunities to scientists from underrepresented groups in brain research. This is achieved by highlighting diverse scientist profiles through a series of interviews; organizing webinars discussing EDI issues, awards, mentoring sessions and networking events; and providing a platform to disseminate data and best practices towards creating a more inclusive brain research community. To discover all our activities and become a member, visit www.alba.network

ANGELINI
Industry Satellite Symposium: ISS.03 — Invitation flyer
Industry Product Theatre: IPT.03 — Invitation flyer

Angelini Pharma is an international pharmaceutical company committed to finding health solutions and helping patients in the areas of Mental Health (including Pain) and Central Nervous System (CNS), Rare Diseases and Consumer Healthcare. Over the past 50 years, in the field of mental health, Angelini Pharma has gained international recognition for its substantial efforts to improve the management of patients with mental health disorders thanks to important, internally developed, molecules and its commitment to fighting mental health stigma.
In 2021, Angelini Pharma strengthened its positioning in the Central Nervous System area with the acquisition of Arvelle Therapeutics.
www.angelinipharma.com

Biogen
Industry Satellite Symposium: ISS.02 — Invitation flyer
Online Exhibition

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers and develops worldwide innovative therapies for people living with serious neurological diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, neuropsychiatry, Alzheimer’s disease and dementia.
www.biogen.com

Boehringer Ingelheim
Industry Satellite Symposium: ISS.07 — Invitation flyer
Industry Satellite Symposium: ISS.10 — Invitation flyer
Online Exhibition

At Boehringer Ingelheim Mental Health, we are redefining mental health to enable people to thrive. We link behaviour to the underlying neurobiology to develop targeted therapies that can ease the burden of these conditions, not just the symptoms. By combining traditional treatment approaches with new and innovative approaches and technologies, we will enable those with mental health conditions to create more meaningful connections to their lives, loved ones and society.
www.boehringer-ingelheim.com
http://annualreport.boehringer-ingelheim.com

EUFAMI
Exhibition stand Lisbon

EUFAMI is a democratic organisation, registered in Belgium as an international non-profit organisation. We have an ongoing commitment to improving care and welfare for people affected by mental illness. We also enable our member organisations to act jointly at a European Level, combining their efforts and sharing experience.
www.eufami.org

European Brain Council (EBC)
Online Exhibition

The European Brain Council (EBC) is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners. A non-profit organisation based in Brussels, its main mission is to promote brain research with the ultimate goal of improving the lives of the estimated 179 million Europeans living with brain conditions. With the aim to speak with one voice, EBC stands as the platform to foster cooperation between its member organisations and other stakeholders, consistently promoting dialogue between scientists, industry and society.
www.braincouncil.eu

European Psychiatric Association (EPA)
Exhibition stand Lisbon

With activities that address the interests of psychiatrists in academia, research and practice throughout all stages of career evolution, the European Psychiatric Association is the main association representing psychiatry in Europe.
Being a part of the EPA means joining a community of practitioners, scientists, and professionals who are committed to the improvement of care for the mentally ill and to the development of professional excellence.
www.europsy.net

FENS Federation of European Neuroscience Societies
Online Exhibition

The Federation of European Neuroscience Societies (FENS) is the voice of European neuroscience. FENS currently represents 44 national and single discipline neuroscience societies with more than 20,000 member scientists from 33 European countries. FENS promotes neuroscience research to policy-makers, funding bodies and the general public, both regionally and internationally. FENS promotes excellence in neuroscience research and facilitates exchanges and networking between neuroscientists within the European Research Area and beyond. The FENS Forum of neuroscience is the main international meeting for brain related research in Europe, its next edition will take place on 9-13 July 2022 in Paris, France.
www.fens.org

GAMIAN-Europe
Exhibition stand Lisbon

Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) is a non-profit patient-driven pan-European organisation, representing and advocating for the interests and rights of persons affected by mental ill-health. Our main activities include awareness-raising, education, and partnership and capacity building. Overarching themes in our work relate to anti-stigma, discrimination and patients’ rights.
www.gamian.eu

Gedeon Richter Plc & RECORDATI S.p.A
Industry Science Exchange: ISE.02 — Invitation flyer
Industry Product Theatre: IPT.02 — Invitation flyer

Headquartered in Hungary, Gedeon Richter is an innovation-driven speciality pharmaceutical company, boasting the biggest pharmaceutical research centre in CEU. Its latest achievement is the original antipsychotic compound, cariprazine, already marketed in the US for BD and schizophrenia treatment and in the majority of the EU countries for the treatment of schizophrenia in adult patients.
https://www.gedeonrichter.com/

Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange, dedicated to the research, development and marketing of pharmaceuticals products. Recordati is committed to the research and development of new specialities in cardiovascular, urological and psychiatric areas with a focus on treatments for rare diseases.
www.recordati.it

Global Medical Education, a Clinical Care Options company/Sunovion
Industry Satellite Symposium: ISS.06 — Invitation flyer

Global Medical Education is one of the leading providers of CME in Psychiatry in the USA. It organizes live meetings, satellite symposia, webcasts and enduring content. GME has partnered with the ECNP for the last 4 years to do satellite symposia and science exchange sessions.
www.gmeded.com

Clinical Care Options (CCO), a leader in innovative, interactive, online, and live CME/CE certified education programs and proprietary medical education technologies, creates and publishes original CME/CE education and information resources that are designed specifically for healthcare professionals. CCO’s educational programs are developed not only to provide the latest clinically relevant, evidence-based education but also to support the understanding, confidence, application, and competence of healthcare professional teams.
www.clinicaloptions.com

Janssen Pharmaceutica NV
Industry Satellite Symposium: ISS.05  — Invitation flyer
Industry Satellite Symposium: ISS.11  — Invitation flyer
Industry Product Theatre: IPT.04 — Invitation flyer
Exhibition stand Lisbon
Online Exhibition
Online Banner

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Janssen Pharmaceutica NV is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Follow us at www.twitter.com/JanssenEMEA.
www.janssen.com/emea

Neuroscience based Nomenclature (NbN)
Exhibition stand Lisbon

Neuroscience based Nomenclature (NbN) is a pharmacologically-driven nomenclature for psychiatric medications based on the unprecedented unique collaboration of five international organizations: ECNP, CINP, ACNP, AsCNP and IUPHAR. It reflects contemporary neuroscience knowledge and replaces the current indication-based nomenclature. NbN lays the ground for rational, precise prescribing for the clinician and decreases stigma and confusion for the patient (no more “anti-depressant” for anxiety and “anti-psychotics” for depression). NbN products include: two books, NbN2R and NbN c&a (child and adolescent), two (free of charge) apps., NbN2 and NbN c&a. So far, NbN apps. have been downloaded by more than 80,000 psychiatrists world-wide.
www.nbn2r.com

Sage Therapeutics and Biogen
Industry Science Exchange: ISE.03  — Invitation flyer

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner.
www.sagerx.com

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis and neuroimmunology; Alzheimer’s disease and dementia; neuromuscular disorders, including spinal muscular atrophy and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics.
www.biogen.com

Saladax
Exhibition stand Lisbon

Diagnostics focused on psychiatry, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians monitor and optimize patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.
www.saladax.com

Sunovion Pharmaceuticals Europe Ltd
Industry Satellite Symposium: ISS.03  — Invitation flyer
Industry Satellite Symposium: ISS.09  — Invitation flyer

At Sunovion Pharmaceuticals Europe Ltd., we focus on the introduction and commercialisation of innovative medicines, with a current specialisation serious in mental health. Sunovion Pharmaceuticals Europe, headquartered in London, is a wholly owned subsidiary of Sunovion Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US.
www.sunovion.eu, www.sunovion.com

Sumitomo Dainippon Pharma
Industry Satellite Symposium: ISS.03  — Invitation flyer

Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area, the Oncology area and Regenerative medicine/Cell therapy field, which have been designated as the focus therapeutic areas. Today Sumitomo Dainippon Pharma has more than 6,000 employees worldwide.
www.ds-pharma.com